Alvotech and Jamp have launched Canada’s first Stelara biosimilar, just a couple of weeks after Alvotech disclosed a settlement that would allow its ustekinumab product to be introduced in markets around the world.

Alvotech and local partner Jamp Pharma have received the first Canadian approval for an ustekinumab biosimilar rival to Stelara in the form of Jamteki, with Health Canada’s marketing authorization following earlier nods for Alvotech’s AVT04 candidate in other geographies.

An important mono- and adjunct therapy for diabetes patients now has generic competition in Canada, where an estimated 10% of the population are said to have been diagnosed with type 1 or type 2 diabetes.

Alvotech has swiftly advanced in Japan and Canada, as part of its mission to introduce its pipeline of biosimilars across the globe.